Project title: TRANSDERMAL DELIVERY SYSTEMS FOR THE TREATMENT OF NEUROLOGICAL DISEASES

Company name : NEURODERM LTD.

TECHNOLOGICAL FIELD
Therapeutics, Medical devices,
Life-Sciences

KEY WORDS
Neurodegenerative,
L-DOPA, Transdermal, Parkinson

PROJECT SUMMARY
NeuroDerm is developing transdermal delivery systems for the
treatment of neurological diseases and related disorders. These
systems are based on unique proprietary formulations and on a
device for maintaining low but constant concentrations of the
active drugs in blood, resulting in more efficacious
pharmacological effects while reducing adverse ones. NeuroDerm
strategy is to use compounds that are approved for human use,
thereby shortening the process of the product approval by the
health authorities. The development efforts are focused on
enhanced transdermal penetration formulations and on a device
delivering a variety of drugs for prolonged periods.
The first product to be developed is a transdermal delivery
system of L-DOPA for the treatment of Parkinson patients.
Transdermal delivery systems for the treatment of Alzheimer
disease and of xerostomia are planned next.

ADVANTAGES
Maintenance of small, but steady, blood concentrations, compared
with intermittent oral administration.
Conferring neuroprotection and prolonging the period of
beneficial effects of the drug by improving its pharmacokinetic
and pharmacodynamic profiles.
Expanding the conventional market of known drugs to new medical
indications.

MARKETS
The primary target market is the population of PD patients who
suffer from late motor fluctuations. This group of patients
constitutes about one third of the total PD patients (1,000,000
in the US and 4,000,000 in the industrial countries). The world
market size of drugs for the treatment of Parkinson disease
exceeds US $3 billion per year.
Currently there is no satisfactory solution for these patients,
and therefore, market penetration is expected to be high within
this group. The product may also be advantageous for the elderly
who have problems with frequent oral administration, as well as
for additional groups of Parkinson patients, with a growth rate
of 10%-20% per year.

ENTREPRENEURS
Prof. Eliahu Heldman - CSO, an
expert in pharmacology, drug development and neurosciences.
Dr. Moshe Kushnir - MD, a
practicing neurologist, the head of the neurology unit in Kaplan
Hospital Rehovot.
Dr. Haim Schlesinger - an analytical
chemist, the president of "Analyst ltd.".
Dr. Alon Yaar - Ph.D.,
General Manager, specializes in management of pre-clinical
studies in the biotech and pharmaceutical industry.

COOPERATION REQUIRED
Strategic partnership with pharmaceutical and drug delivery
companies to finance clinical trials as well as enter marketing
alliances, looking forward for exit opportunities within 3 to 4
years from the start-up of the company.

Request for more information, about this project.

Note - you have to be registered in this server to request information. If you haven't done so yet, please:
Register in this server and your requests will be forwarded to the developer, who will contact you directly

List of projects that you already requested more information about